WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX), will hold a conference call to discuss its newly-disclosed license agreement with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) for EP-3102, Eagle’s bendamustine hydrochloride (HCl) rapid infusion product. Interested parties may access the call as follows:
Help employers find you! Check out all the jobs and post your resume.
